Job Trends
The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
Looking for a biopharma job in Boston? Check out the BioSpace list of six companies hiring life sciences professionals like you.
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
THE LATEST
A University of Houston engineering professor is examining the life cycle of stubborn, drug-resistant persister cells in recurrent infections to find a way to destroy them.
The biotech Hotbed known as Pharm Country, which includes New Jersey, Connecticut, New York Pennsylvania and Rhode Island, is an area of rapid growth and change.
The focus is on containment, although a number of organizations and companies are beginning work on vaccines.
It was another busy week for clinical trial updates. Here’s a look.
Kansas City, KS- SEKISUI XenoTech announces the promotion of Dr. Darren Warren, PhD to President and Chief Executive Officer.
All three companies have invested millions in the facilities to expand their global footprint.
Lilly said the donation of the KwikPens will help expand health care access and improve the quality of care for people with diabetes across the U.S.
The approval was based on two randomized open-label clinical trials that evaluated the combination of empagliflozin, linagliptin and metformin and their individual components in healthy adults.
The week after the JP Morgan Healthcare Conference tends to be slower than the week of, and last week was no outlier. Still, there were clinical trial updates. Here’s a look.
The positions will be in manufacturing, assembly and packaging. The NC Department of Commerce approved the incentives this morning.